Close this search box.

We are creating some awesome events for you. Kindly bear with us.

Taiwan’s Latest Biotech Innovations

With COVID-19 dramatically changing the healthcare industry, organisations have been forced to adapt their practices and embrace digital transformation. Hence, Taiwan’s Development Center of Biotechnology (DCB) is prepared to demonstrate Taiwan’s pharmaceutical innovation on new cancer drugs and cell therapies in the world’s largest virtual biotech.

Twelve innovative drug discovery technologies have been selected to be displayed. DCB then invited many government officials, tech and health experts to discuss issues on public health, pharmaceuticals, therapeutics, Artificial Intelligence (AI), and strategies to boost bio-innovation under the pandemic. This initiative is supported by Taiwan’s Department of Industrial Technology (DoIT) under the Ministry of Economic Affairs (MOEA).

To cope with future infectious diseases and the fast-changing COVID-19 variants, Taiwan must utilise its strengths in Information and Communications Technology, AI, and data analytics to improve its healthcare system. These technologies can also minimise physical contact and facilitate smart hospital management in the hospital. Furthermore, the global collaborations between governments and biotech companies have shown the importance of solidarity in combating the pandemic.

The first biotech innovation on display is the FLT3 inhibitor for patients with acute myeloid leukaemia (AML) shows promise in the AML market since its 5-year survival rate is only 15% to 20%, and this drug candidate is proven to be highly specific and can induce high activity.

Next is the Tri-mannosyl-ADC platform, an antibody-drug conjugate (ADC) developed by DCB. It is created by using enzymes to combine chemicals in the form of 4 single molecules (4A) or 2 different molecules (2A2B) with antibodies. Compared to other ADC drugs, the Tri-mannosyl-ADC platform demonstrated a higher potential to increase efficacy and overcome certain adverse events, making it a better candidate to commercialise.

In addition, DCB developed a new CAR-T therapy with an autocrine immune checkpoint inhibitor and new targets. In the lab setting, the therapy expressed high specificity and toxicity toward the solid tumour in gastric cancer, showing 60% effectiveness on tumour inhibition. DCB now is expecting to tackle issues with the tumour microenvironment and leads to a stronger cytotoxic effect on solid tumours. DCB then developed a high throughput CHO cell production system with great potential in the market. The technology would be one of the main focuses in the display and would attract biopharma firms.

During the display, two leading Taiwanese start-ups are also set to exhibit their product portfolios. Taiwan’s medical device company will showcase a smart remote management system including curative effect tracking and treatment management cloud platform. A smart health company will present its digital therapeutics that provide customised, scalable, and data-driven chronic disease management. The platform was deployed across 240 healthcare providers and has been available for more than 650,000 patients in Taiwan and Japan.

The pandemic drove drug discovery and selection to an unprecedented speed. It forced pharmaceutical companies to come up with new drug innovations within months. By utilising the power of AI, data science, and genomics, the fast-paced innovations are feasible. The biotech display is a great opportunity to show the world Taiwan’s unique viewpoints and development in biotech, AI, digital medicine, and drug discovery. Taiwanese firms must venture for more overseas channels and business opportunities.

Taiwan has been focusing on utilising advanced technologies in the health sector including promoting the use of AI. As reported by OpenGov Asia, healthcare is the ideal field to expand the use of AI given the technology’s ability to quickly conduct big data analyses and modelling. Taiwan’s National Health Insurance (NHI) Research Database contains over two decades worth of data and images to assist in this process. Taiwan is also an ideal place to integrate the latest and greatest technologies into the biotech and medical sectors.


Qlik’s vision is a data-literate world, where everyone can use data and analytics to improve decision-making and solve their most challenging problems. A private company, Qlik offers real-time data integration and analytics solutions, powered by Qlik Cloud, to close the gaps between data, insights and action. By transforming data into Active Intelligence, businesses can drive better decisions, improve revenue and profitability, and optimize customer relationships. Qlik serves more than 38,000 active customers in over 100 countries.


CTC Global Singapore, a premier end-to-end IT solutions provider, is a fully owned subsidiary of ITOCHU Techno-Solutions Corporation (CTC) and ITOCHU Corporation.

Since 1972, CTC has established itself as one of the country’s top IT solutions providers. With 50 years of experience, headed by an experienced management team and staffed by over 200 qualified IT professionals, we support organizations with integrated IT solutions expertise in Autonomous IT, Cyber Security, Digital Transformation, Enterprise Cloud Infrastructure, Workplace Modernization and Professional Services.

Well-known for our strengths in system integration and consultation, CTC Global proves to be the preferred IT outsourcing destination for organizations all over Singapore today.


Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions creates an organizational focus on the strategic outcomes that matter and empowers teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,300 employees supporting 4,500 customers and 2.6 million users worldwide. For more information, visit


SIRIM is a premier industrial research and technology organisation in Malaysia, wholly-owned by the Minister​ of Finance Incorporated. With over forty years of experience and expertise, SIRIM is mandated as the machinery for research and technology development, and the national champion of quality. SIRIM has always played a major role in the development of the country’s private sector. By tapping into our expertise and knowledge base, we focus on developing new technologies and improvements in the manufacturing, technology and services sectors. We nurture Small Medium Enterprises (SME) growth with solutions for technology penetration and upgrading, making it an ideal technology partner for SMEs.


HashiCorp provides infrastructure automation software for multi-cloud environments, enabling enterprises to unlock a common cloud operating model to provision, secure, connect, and run any application on any infrastructure. HashiCorp tools allow organizations to deliver applications faster by helping enterprises transition from manual processes and ITIL practices to self-service automation and DevOps practices. 


IBM is a leading global hybrid cloud and AI, and business services provider. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Nearly 3,000 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and business services deliver open and flexible options to our clients. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity and service.